NanoKnife® procedure

Edward Hospital is one of only a few hospitals in the Chicago area to offer NanoKnife®, another option used to treat certain patients with advanced pancreatic, liver and soft tissue cancers.

The NanoKnife® system offers a less invasive treatment option for patients with inoperable or difficult-to-reach tumors who are not candidates for conventional treatments. NanoKnife® is typically one part of a patient's treatment, along with chemotherapy and radiation.

What's involved in the NanoKnife® procedure?

The NanoKnife® system uses electrical currents to treat tumors. Thin needles are strategically placed around the tumor. Then, the system sends currents between the needles in a process called irreversible electroporation (IRE), which helps to destroy the tumor.

What are the advantages of NanoKnife®?

Since the electrical pulses are contained, the NanoKnife® system helps to minimize damage to surrounding healthy cell tissue other important structures, resulting in few to no side effects.

Who is eligible for NanoKnife®?

Not all patients meet the criteria for the NanoKnife® procedure. It may be an option if you have an inoperable or difficult-to-reach tumor and your other treatments were not effective. Patients with cardiac issues are not eligible for this procedure.

You, your surgical oncologist and the rest of your care team will determine if NanoKnife® is appropriate for you.

What are the next steps?

For more information or to schedule a patient consultation, call 630-527-3788.

Learn more about our care team

Related Clinical Trials

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer...
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating...
Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in high risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher...
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy...